Mirzotamab clezutoclax

Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) with three components: an anti-B7-H3 monoclonal antibody, and BCL2L1 (BCL-XL) inhibitor Clezutoclaxum (HY-137774) . Mirzotamab clezutoclax can be used for the study of relapsed and/or refractory (R/R) solid tumors[1].

Product Specifications

CAS Number

[2229859-12-3]

Product Name Alternative

ABBV-155

UNSPSC

12352100

Target

Antibody-Drug Conjugates (ADCs) ; Bcl-2 Family; CD276/B7-H3

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

[Mirzotamabclezutoclax]

References & Citations

[1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.